Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March 5, 2018
CAMBRIDGE, Mass. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2017 financial
View HTML
Toggle Summary Vericel to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the BIO CEO &
View HTML
Toggle Summary Vericel to Present at the 7th Annual Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 7 th Annual
View HTML
Toggle Summary Vericel to Present at the 20th Annual Needham Growth Conference
CAMBRIDGE, Mass. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
View HTML
Toggle Summary Vericel Initiates Collaboration with Innovative Cellular Therapeutics
CAMBRIDGE, Mass. and SHANGHAI, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the initiation of its License Agreement with
View HTML
Toggle Summary Vericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley Bank and MidCap Financial to Support Accelerating MACI Uptake and Increased Epicel Usage
Facilities Include a $15 Million Term Loan and $10 Million Revolving Line of Credit CAMBRIDGE, Mass. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions,
View HTML
Toggle Summary Vericel to Present at 29th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
View HTML
Toggle Summary Vericel Reports Third-Quarter 2017 Financial Results
Record Third Quarter Revenue of $14.3 Million Represents a 30% Increase Over Third Quarter 2016   Results Driven by Continued Momentum of MACI Uptake and Expanded Epicel Usage   Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) --  Vericel Corporation
View HTML
Toggle Summary Vericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
View HTML
Toggle Summary Vericel Provides Business Updates at 2017 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today provided a general business update during a previously announced webcast
View HTML